^
BIOMARKER:

Chr del(11q)

Chr del(11q)
CLL
ibrutinib
Sensitive: A2 - Guideline
Chr del(11q)
CLL
rituximab
Resistant: A2 - Guideline
Chr del(11q)
CLL
obinutuzumab + acalabrutinib
Sensitive: A2 - Guideline
Chr del(11q)
CLL
ibrutinib + ublituximab
Sensitive: B - Late Trials
Chr del(11q)
CLL
zanubrutinib
Sensitive: B - Late Trials
Chr del(11q)
CLL
obinutuzumab
Resistant: B - Late Trials
Chr del(11q)
Small Lymphocytic Lymphoma
ibrutinib
Sensitive: B - Late Trials
Chr del(11q)
Small Lymphocytic Lymphoma
zanubrutinib
Sensitive: B - Late Trials
Chr del(11q)
CLL
acalabrutinib
Sensitive: B - Late Trials
Chr del(11q)
CLL
venetoclax
Sensitive: C2 – Inclusion Criteria
Chr del(11q)
CLL
lenalidomide + tafasitamab
Sensitive: C3 – Early Trials
Chr del(11q)
CLL
RP6530
Sensitive: C3 – Early Trials
Chr del(11q)
Small Lymphocytic Lymphoma
ICP-022
Sensitive: C3 – Early Trials
Chr del(11q)
CLL
ICP-022
Sensitive: C3 – Early Trials
Chr del(11q)
CLL
venetoclax + ibrutinib
Sensitive: C3 – Early Trials
Chr del(11q)
Multiple Myeloma
obinutuzumab
Resistant: C3 – Early Trials
Chr del(11q)
CLL
duvelisib
Sensitive: C3 – Early Trials
Chr del(11q)
CLL
FCR
Sensitive: C3 – Early Trials
Chr del(11q)
CLL
ibrutinib + UC-961
Sensitive: C3 – Early Trials
Chr del(11q)
CLL
Compound C
Sensitive: D – Preclinical
Chr del(11q)
CLL
hydroxychloroquine
Sensitive: D – Preclinical
Chr del(11q)
CLL
MRT68921
Sensitive: D – Preclinical